Polytherapy Beats Monotherapy as Second-Line Treatment for NSCLC


Combining targeted therapy improves overall survival for patients with non-small cell lung cancer (NSCLC), compared to using the targeted drug erlotinib (Tarceva) alone, according to a recent study. By pooling data from eight clinical trials, researchers found that patient outcomes were improved when combination therapy was used as a second-line treatment for NSCLC.

Patients with advanced NSCLC who have already received initial therapy usually take erlotinib alone as a second-line treatment. Erlotinib directly targets the EGFR protein and can be particularly effective for patients with mutations in the EGFR gene. Continue reading…